title: [The effect of PKC-delta inhibitor Rottlerin on human colon cancer cell line SW1116 and its mechanism].
abstract: OBJECTIVE
  To evaluate the effect of PKC-delta inhibitor Rottlerin on human colon cancer cells and its mechanism.
  
  
  METHODS
  Human colon cancer cell line SW1116 cells were treated with Rottlerin. The transcriptional level of DNA methyltransferase (Dnmt)1, Dnmt3a and Dnmt3b was detected by real-time RT-PCR. Cell cycle distribution was evaluated by flow cytometry (FCM). In addition, cellular morphological changes were examined by light microscopy.
  
  
  RESULTS
  PKC-delta inhibitor decreased the expression of Dnmt1, Dnmt3a mRNA, up-regulated APC, p21(WAF1) and p16(INK4A) mRNA. Demonstarted by flow cytometry, Rottlerin increased the percentage of cell cycle G0/G1 phase cell numbers (P = 0.02) and decreased the percentage of cell cycle G2/M phase cell numbers (P = 0.01). Remarkable changes of cellular morphology were observed under light microscope: The volume and cytoplasm of cells treated with Rottlerin were increased. The cell contour was not very clear, and mitotic figures were less frequently seen.
  
  
  CONCLUSIONS
  PKC-delta inhibitor Rottlerin inhibites cell division and proliferation of the colon cancer SW1116 cells through regulating DNA methylation and blocking the signaling pathway of mitogen-activated protein kinase (MAPK).
authors.affiliation: Institute of Digestive Diseases, Renji Hospital, Shanghai Second Medical University, Shanghai 200001, China.
authors.forename: Zhao-fei
authors.initials: ZF
authors.lastname: Chen
authors.forename: Jing-yuan
authors.initials: JY
authors.lastname: Fang
authors.forename: Yu-rong
authors.initials: YR
authors.lastname: Weng
authors.forename: Dan-feng
authors.initials: DF
authors.lastname: Sun
authors.forename: Xia
authors.initials: X
authors.lastname: Wang
authors.forename: Rong
authors.initials: R
authors.lastname: Lu
mesh_terms: D000098:Acetophenones / Q000494:pharmacology*; D025601:Adenomatous Polyposis Coli Protein / Q000235:genetics; D001578:Benzopyrans / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D003110:Colonic Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000235:genetics; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000235:genetics; D000076123:DNA (Cytosine-5-)-Methyltransferase 1; D004248:DNA (Cytosine-5-)-Methyltransferases / Q000235:genetics; D000090205:DNA Methyltransferase 3A; D005434:Flow Cytometry; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D006801:Humans; D051745:Protein Kinase C-delta / Q000037:antagonists & inhibitors*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000098:Acetophenones; D025601:Adenomatous Polyposis Coli Protein; D001578:Benzopyrans; C493956:CDKN1A protein, human; D019941:Cyclin-Dependent Kinase Inhibitor p16; D050759:Cyclin-Dependent Kinase Inhibitor p21; C000717967:DNMT3A protein, human; D012333:RNA, Messenger; C085746:rottlerin; D000076123:DNA (Cytosine-5-)-Methyltransferase 1; D004248:DNA (Cytosine-5-)-Methyltransferases; D000090205:DNA Methyltransferase 3A; C000619380:DNMT1 protein, human; D051745:Protein Kinase C-delta